aminopyridines

Summary

Summary: Pyridines substituted in any position with an amino group. May be hydrogenated, but must retain at least one double bond.

Top Publications

  1. ncbi The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
    Armin Hatzelmann
    Nycomed GmbH, Konstanz, Germany
    Pulm Pharmacol Ther 23:235-56. 2010
  2. ncbi Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
    Peter M A Calverley
    School of Clinical Sciences, Liverpool, UK
    Lancet 374:685-94. 2009
  3. ncbi Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
    Peter M A Calverley
    Department of Medicine, Clinical Sciences, University Hospital Aintree, Liverpool L97AL, UK
    Am J Respir Crit Care Med 176:154-61. 2007
  4. ncbi Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
    Leonardo M Fabbri
    University of Modena and Reggio Emilia, Modena, Italy
    Lancet 374:695-703. 2009
  5. ncbi Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD
    Stephen I Rennard
    Nebraska Medical Center, Omaha, Nebraska, USA
    Respir Res 12:18. 2011
  6. ncbi Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
    Diana C Grootendorst
    Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
    Thorax 62:1081-7. 2007
  7. ncbi S100A13 is involved in the regulation of fibroblast growth factor-1 and p40 synaptotagmin-1 release in vitro
    C Mouta Carreira
    Center for Molecular Medicine, Maine Medical Center Research Institute, South Portland, Maine 04106, USA
    J Biol Chem 273:22224-31. 1998
  8. ncbi Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease
    Francisco J Soto
    Division of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Curr Opin Pulm Med 11:129-34. 2005
  9. ncbi Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice
    Piero A Martorana
    Department of Physiopathology and Experimental Medicine, University of Siena, Siena, Italy
    BMC Pulm Med 8:17. 2008
  10. ncbi PDE4 inhibitors: a review of current developments (2005 - 2009)
    Lluís Pagès
    Almirall R and D Centre, Department of Medicinal Chemistry, Laurea Miro 408 410, 08980 Sant Feliu de Llobregat, Barcelona, Spain
    Expert Opin Ther Pat 19:1501-19. 2009

Research Grants

  1. STRUCTURE-FUNCTION IN LOW-RESISTANCE JUNCTIONS
    Camillo Peracchia; Fiscal Year: 1993
  2. METVAN: A Novel Anticancer Agent
    OSMOND D CRUZ; Fiscal Year: 2003
  3. FLP-102: Rationally Engineered Antiviral Protein
    OSMOND D CRUZ; Fiscal Year: 2003
  4. Stampidine: A Novel Broad-Spectrum Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
  5. Phase II SBIR: WHI-07: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
  6. Transmitter Repletion: Key to Phrenic-Diaphragm Function
    Erik van Lunteren; Fiscal Year: 2005
  7. NOVEL CONTRACEPTIVES WITH ANTI-HIV ACTIVITY
    OSMOND D CRUZ; Fiscal Year: 2001
  8. PHI 346: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
  9. PHI-443: Novel Non-Spermicidal Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
  10. Vanadocenes as a New Class of Spermicidal Drugs
    OSMOND D CRUZ; Fiscal Year: 2007

Detail Information

Publications186 found, 100 shown here

  1. ncbi The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
    Armin Hatzelmann
    Nycomed GmbH, Konstanz, Germany
    Pulm Pharmacol Ther 23:235-56. 2010
    ..This enables roflumilast to offer effective, oral maintenance treatment for COPD, with an acceptable tolerability profile and the potential to favourably affect the extrapulmonary effects of the disease...
  2. ncbi Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
    Peter M A Calverley
    School of Clinical Sciences, Liverpool, UK
    Lancet 374:685-94. 2009
    ..We therefore investigated whether roflumilast would reduce the frequency of exacerbations requiring corticosteroids in patients with COPD...
  3. ncbi Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
    Peter M A Calverley
    Department of Medicine, Clinical Sciences, University Hospital Aintree, Liverpool L97AL, UK
    Am J Respir Crit Care Med 176:154-61. 2007
    ..Whether treatment is effective in more severe COPD (GOLD [Global Initiative for Chronic Obstructive Lung Disease] stages III and IV) over a longer period is unknown...
  4. ncbi Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials
    Leonardo M Fabbri
    University of Modena and Reggio Emilia, Modena, Italy
    Lancet 374:695-703. 2009
    ..The effect of roflumilast on lung function in patients with COPD that is moderate to severe who are already being treated with salmeterol or tiotropium was investigated...
  5. ncbi Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD
    Stephen I Rennard
    Nebraska Medical Center, Omaha, Nebraska, USA
    Respir Res 12:18. 2011
    ..This led to the question of whether a responsive subset existed that could be investigated further...
  6. ncbi Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
    Diana C Grootendorst
    Department of Pulmonology, Leiden University Medical Center, Leiden, The Netherlands
    Thorax 62:1081-7. 2007
    ..Results from in vitro studies with roflumilast indicate that it has anti-inflammatory properties that may be applicable for the treatment of COPD...
  7. ncbi S100A13 is involved in the regulation of fibroblast growth factor-1 and p40 synaptotagmin-1 release in vitro
    C Mouta Carreira
    Center for Molecular Medicine, Maine Medical Center Research Institute, South Portland, Maine 04106, USA
    J Biol Chem 273:22224-31. 1998
    ....
  8. ncbi Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease
    Francisco J Soto
    Division of Pulmonary and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    Curr Opin Pulm Med 11:129-34. 2005
    ..Novel anti-inflammatory therapies such as selective phosphodiesterase 4 (PDE4) inhibitors are in clinical development. Their potential role in the management of COPD is described in this review...
  9. ncbi Effect of roflumilast on inflammatory cells in the lungs of cigarette smoke-exposed mice
    Piero A Martorana
    Department of Physiopathology and Experimental Medicine, University of Siena, Siena, Italy
    BMC Pulm Med 8:17. 2008
    ..Here we investigated the effects of roflumilast on the volume density (VV) of the inflammatory cells present in the lungs after chronic cigarette smoke exposure...
  10. ncbi PDE4 inhibitors: a review of current developments (2005 - 2009)
    Lluís Pagès
    Almirall R and D Centre, Department of Medicinal Chemistry, Laurea Miro 408 410, 08980 Sant Feliu de Llobregat, Barcelona, Spain
    Expert Opin Ther Pat 19:1501-19. 2009
    ..Despite the sound preclinical database and some promising data from clinical trials, development of PDE4 inhibitors for the treatment of inflammatory or neurological diseases has been hampered by dose-limiting class-related side effects...
  11. ncbi Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects
    Nassr Nassr
    Nycomed GmbH, 78467 Konstanz, Germany
    Br J Clin Pharmacol 68:580-7. 2009
    ..Roflumilast is metabolized by CYP3A4 and CYP1A2, with further involvement of CYP2C19 and extrahepatic CYP1A1. In vivo, roflumilast N-oxide contributes >90% to the total PDE4 inhibitory activity...
  12. ncbi Phosphodiesterase type 4 inhibitors cause proinflammatory effects in vivo
    Kerryn McCluskie
    Department of Pharmacology, Theravance Inc, South San Francisco, California, USA
    J Pharmacol Exp Ther 319:468-76. 2006
    ..The proinflammatory cytokines KC and IL-8 therefore may provide surrogate biomarkers, both in preclinical animal models and in the clinic, to assess potential proinflammatory effects of this class of compounds...
  13. ncbi Effect of fluvoxamine on the pharmacokinetics of roflumilast and roflumilast N-oxide
    Oliver von Richter
    Exploratory Medicine, ALTANA Pharma AG, Konstanz, Germany
    Clin Pharmacokinet 46:613-22. 2007
    ....
  14. ncbi Differential effects of the 5-HT(2A) receptor antagonist M100907 and the 5-HT(2C) receptor antagonist SB242084 on cocaine-induced locomotor activity, cocaine self-administration and cocaine-induced reinstatement of responding
    Paul J Fletcher
    Departments of Psychiatry and Psychology, University of Toronto, Toronto, Ontario, Canada
    Neuropsychopharmacology 27:576-86. 2002
    ..These results indicate distinct, and in some cases opposite, effects of a 5-HT(2A) compared with a 5-HT(2C) receptor antagonist on various cocaine-mediated behavioral effects...
  15. ncbi Differential regulation of the mesoaccumbens dopamine circuit by serotonin2C receptors in the ventral tegmental area and the nucleus accumbens: an in vivo microdialysis study with cocaine
    Sylvia Navailles
    Unité Mixte de Recherche Centre National de la Recherche Scientifique UMR CNRS 5541, Universite Victor Segalen Bordeaux 2, Bordeaux Cedex, France
    Neuropsychopharmacology 33:237-46. 2008
    ....
  16. ncbi 5-Amino-6-chloro-N-[(1-isobutylpiperidin-4-yl)methyl]-2-methylimidazo[1,2-alpha]pyridine-8-carboxamide (CJ-033,466), a novel and selective 5-hydroxytryptamine4 receptor partial agonist: pharmacological profile in vitro and gastroprokinetic effect in consc
    Tadayoshi Mikami
    Drug Safety Research and Development, Tokyo Laboratories, Pfizer Global Research and Development, Pfizer Inc, 3 22 7 Yoyogi, Shibuya, Tokyo 151 8589, Japan
    J Pharmacol Exp Ther 325:190-9. 2008
    ..Therefore, CJ-033,466 could be used to treat gastroparesis, providing better gastroprokinetics and reduced side effects mediated by the other receptors...
  17. ncbi Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model
    Gezim Lahu
    Department of Pharmacometrics and Pharmacokinetics, Nycomed GmbH, Byk Gulden Strasse 2, Konstanz, Germany
    Clin Pharmacokinet 49:589-606. 2010
    ..Both roflumilast and its metabolite roflumilast N-oxide have anti-inflammatory properties that contribute to overall pharmacological activity...
  18. ncbi A phosphodiesterase 4 inhibitor, roflumilast N-oxide, inhibits human lung fibroblast functions in vitro
    F Sabatini
    Pulmonary Disease Unit, G Gaslini Institute, Largo G Gaslini 5, 16147 Genoa, Italy
    Pulm Pharmacol Ther 23:283-91. 2010
    ..Taken together, these findings indicate that roflumilast N-oxide directly targets human lung fibroblasts, which may at least partially explain the efficacy of roflumilast to mitigate a pulmonary fibrotic response in vivo...
  19. ncbi Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors
    J Nicole Hamblin
    GlaxoSmithKline Medicines Research Centre, Gunnels Wood Road, Stevenage, Hertfordshire SG1 2NY, UK
    Bioorg Med Chem Lett 18:4237-41. 2008
    ....
  20. ncbi No dose adjustment on coadministration of the PDE4 inhibitor roflumilast with a weak CYP3A, CYP1A2, and CYP2C19 inhibitor: an investigation using cimetidine
    Gabriele M Böhmer
    Department of Clinical Pharmacology, University Hospital of Tubingen, Tubingen, Germany
    J Clin Pharmacol 51:594-602. 2011
    ..These moderate changes indicate that dose adjustment of roflumilast is not required when coadministered with a weak inhibitor of CYP1A2, CYP3A, and CYP2C19, such as cimetidine...
  21. ncbi Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide
    Gezim Lahu
    Nycomed GmbH, Konstanz, Germany
    J Clin Pharmacol 51:586-93. 2011
    ..Roflumilast was well tolerated both alone and in combination with enoxacin. A weak interaction was shown between roflumilast and enoxacin, as mean tPDE4i increased by 25%, but is unlikely to have clinical relevance...
  22. ncbi Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease
    Brian J Lipworth
    Department of Medicine and Therapeutics, Asthma and Allergy Research Group, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK
    Lancet 365:167-75. 2005
    ..Ultimately, clinicians will want to know whether PDE4 inhibitors are anything more than expensive "designer" theophylline, the archetypal non-selective phosphodiesterase inhibitor...
  23. ncbi Roflumilast inhibits leukocyte-endothelial cell interactions, expression of adhesion molecules and microvascular permeability
    M J Sanz
    Department of Pharmacology, University of Valencia, Valencia, Spain
    Br J Pharmacol 152:481-92. 2007
    ..The present study addressed the effects of the investigational PDE4 inhibitor roflumilast on leukocyte-endothelial cell interactions and endothelial permeability in vivo and in vitro...
  24. ncbi An evaluation on the efficacy and safety of amlexanox oral adhesive tablets in the treatment of recurrent minor aphthous ulceration in a Chinese cohort: a randomized, double-blind, vehicle-controlled, unparallel multicenter clinical trial
    Jie Liu
    Department of Oral Medicine, West China College of Stomatology, Suchuan University, Sichuan, China
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:475-81. 2006
    ..05). No systemic side effects were reported. CONCLUSIONS: Amlexanox oral adhesive tablets are effective and safe in reducing aphthous ulcer pain and lesion size, as well as erythema and exudation in this Chinese cohort...
  25. ncbi The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo
    Wolfgang Timmer
    Byk Gulden Pharmaceuticals, Konstanz, Germany
    J Clin Pharmacol 42:297-303. 2002
    ..It is concluded that roflumilast is effective in the treatment of exercise-induced asthma. This result was accompanied by a significant reduction of TNF-alpha levels ex vivo. Treatment with roflumilast was safe and well tolerated...
  26. ncbi Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects
    Nassr Nassr
    ALTANA Pharma AG, 78467 Konstanz, Germany
    Br J Clin Pharmacol 63:365-70. 2007
    ..The aim of this study was to investigate the effects of roflumilast, an investigational PDE4 inhibitor for the treatment of COPD and asthma, on the pharmacokinetics of the CYP3A probe drug midazolam and its major metabolites...
  27. ncbi Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions
    Emmerentia van Schalkwyk
    Department of Internal Medicine, University of Stellenbosch, Cape Town
    J Allergy Clin Immunol 116:292-8. 2005
    ..Pronounced suppression of late responses in an allergen challenge model suggests that roflumilast might have anti-inflammatory activity, which could provide clinical efficacy in chronic inflammatory pulmonary diseases, such as asthma...
  28. ncbi Investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects
    Bernhard Hauns
    Department of Clinical Pharmacology, ALTANA Pharma AG, Byk Gulden Str 2, D 78467 Konstanz, Germany
    J Clin Pharmacol 46:1146-53. 2006
    ..91; 90% CI, 0.79-1.04; PE, 0.99; 90% CI, 0.92-1.06) occurred. Because roflumilast N-oxide is the major contributor to roflumilast's overall pharmacologic effects, these findings suggest that roflumilast can be taken with or without food...
  29. ncbi PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression
    Maria Jesus Sanz
    Department of Pharmacology, Faculty of Medicine, University of Valencia, Avenida Blasco Ibanez 15, E 46010 Valencia, Spain
    Pharmacol Ther 106:269-97. 2005
    ..These new drugs may also offer opportunities for treatment of other inflammatory diseases...
  30. ncbi The efficacy of amlexanox OraDisc on the prevention of recurrent minor aphthous ulceration
    B Murray
    The Oral Science Research Centre, School of Dentistry, Queen's University Belfast, Royal Group Hospitals and Dental Hospital, Belfast, UK
    J Oral Pathol Med 35:117-22. 2006
    ..CONCLUSION: The OraDisc prevents ulcers from developing when compared with the vehicle patch...
  31. ncbi Roflumilast inhibition of pulmonary leukotriene production and bronchoconstriction in ovalbumin-sensitized and -challenged Guinea pigs
    Lutz Wollin
    ALTANA Pharma, Konstanz, Germany
    J Asthma 42:873-8. 2005
    ..06 mg/kg) and LTB4 (ID50 = 0.05 mg/kg) release versus placebo-treated animals. Roflumilast did not affect LTD4-induced bronchoconstriction. These findings support the role of roflumilast as an anti-inflammatory treatment for asthma...
  32. ncbi Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors
    L Wollin
    ALTANA Pharma, Byk Gulden Strasse 2, 78467 Konstanz, Germany
    Pulm Pharmacol Ther 19:343-52. 2006
    ..This study suggests that roflumilast has anti-inflammatory action and provides rationale for the investigation of roflumilast in asthmatic patients...
  33. ncbi A comparative study of the efficacy of Aphtheal in the management of recurrent minor aphthous ulceration
    Brenda Murray
    The Oral Science Research Centre, School of Dentistry, Queen's University Belfast, UK
    J Oral Pathol Med 34:413-9. 2005
    ..01) compared to no treatment. CONCLUSION: Treatment with Aphtheal at the onset of prodromal RAU symptoms can prevent progression to ulcer development and significantly reduced symptoms if ulcers do develop...
  34. ncbi Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation
    Hyun Jeong Kwak
    Laboratory of Molecular Pharmacology and Physiology, Medicinal Science Division, Korea Research Institute of Chemical Technology, P.O. Box 107, Yusung-gu, Taejon 305-343, Korea
    J Pharmacol Exp Ther 315:1188-95. 2005
    ..These results suggest that the inhibitory activity of roflumilast on the production of inflammatory mediators seems to be mediated via inhibition of NF-kappaB, p38 MAP kinase, and JNK activation in macrophages...
  35. ncbi Roflumilast--an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial
    Klaus F Rabe
    Leiden University Medical Centre, Leiden, Netherlands
    Lancet 366:563-71. 2005
    ..There are few treatment options for the disease. This study assessed the efficacy and safety of roflumilast, a phosphodiesterase-4 inhibitor, in patients with moderate to severe COPD...
  36. ncbi Roflumilast, a once-daily oral phosphodiesterase 4 inhibitor, lacks relevant pharmacokinetic interactions with inhaled salbutamol when co-administered in healthy subjects
    T D Bethke
    ALTANA Pharma AG, Konstanz, Germany
    Int J Clin Pharmacol Ther 44:572-9. 2006
    ..10 (0.99, 1.21), 1.08 (0.91, 1.28). The combination of both drugs was well tolerated. CONCLUSION: There were no relevant pharmacokinetic interactions between roflumilast and salbutamol at therapeutically effective doses...
  37. ncbi Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor
    Thomas D Bethke
    Department of Clinical Development Strategy, ALTANA Pharma AG, Konstanz, Germany
    J Clin Pharmacol 47:26-36. 2007
    ..Repeated oral dosing with roflumilast 250 and 500 microg once daily was well tolerated...
  38. ncbi The targeted oral, once-daily phosphodiesterase 4 inhibitor roflumilast and the leukotriene receptor antagonist montelukast do not exhibit significant pharmacokinetic interactions
    Gabriele M Böhmer
    Department of Clinical Pharmacology, University Hospital of Tubingen, Otfried Müller Str 45, D 72076 Tubingen, Germany
    J Clin Pharmacol 49:389-97. 2009
    ..Concomitant administration of both drugs was well tolerated. These findings suggest that no dose adjustment is warranted for either drug when roflumilast and montelukast are coadministered...
  39. ncbi PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts
    Shinsaku Togo
    Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, NE 68198 5885, USA
    Am J Physiol Lung Cell Mol Physiol 296:L959-69. 2009
    ..The present study supports the concept that PDE4 inhibitors may attenuate fibroblast activities that can lead to fibrosis and that PDE4 inhibitors may be particularly effective in the presence of TGF-beta1-induced fibroblast stimulation...
  40. ncbi Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide
    Gezim Lahu
    Nycomed GmbH, Department of Pharmacometrics and Pharmacokinetics, Byk Gulden Str 2, 78467 Konstanz, Germany
    J Clin Pharmacol 48:1339-49. 2008
    ..No clinically relevant adverse events were observed. Coadministration of ketoconazole and roflumilast does not require dose adjustment of roflumilast...
  41. ncbi Single-dose pharmacokinetics of roflumilast in children and adolescents
    Kathleen A Neville
    Department of Pediatrics, University of Missouri Kansas City and the Children s Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64079, USA
    J Clin Pharmacol 48:978-85. 2008
    ..1 and 0.8 microg/L per 1 microg/kg dose for adolescents and children, respectively), pharmacokinetic parameters for roflumilast and roflumilast N-oxide were not different between age groups and were similar to adults...
  42. ncbi Roflumilast attenuates pulmonary inflammation upon segmental endotoxin challenge in healthy subjects: a randomized placebo-controlled trial
    Jens M Hohlfeld
    Department of Clinical Airway Research, Fraunhofer Institute of Toxicology and Experimental Medicine ITEM, Nikolai Fuchs Street 1A, D 30625 Hannover, Germany
    Pulm Pharmacol Ther 21:616-23. 2008
    ..Roflumilast, an investigational, targeted phosphodiesterase 4 inhibitor, reduces the in vitro and in vivo inflammatory activity of cells such as neutrophils, eosinophils, macrophages, and monocytes...
  43. ncbi PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
    Victoria Boswell Smith
    The Sackler Institute of Pulmonary Pharmacology, King s College London School of Biomedical and Health Sciences, King s College London, Guys Campus, UK
    Int J Chron Obstruct Pulmon Dis 2:121-9. 2007
    ..This review will discuss the current standing of PDE4 inhibitors like roflumilast as novel treatments for COPD and the potential for developing nonemetic anti-inflammatory drugs...
  44. ncbi The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide
    Robert Hermann
    ALTANA Pharma AG, Konstanz, Germany
    J Clin Pharmacol 47:1005-13. 2007
    ..67, 1.50). Coadministration of roflumilast and budesonide did not alter the steady-state disposition of each other and did not affect safety and tolerability of either drug...
  45. ncbi Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion
    Atsushi Kuno
    Department of Physiology, MSB 3074, University of South Alabama, College of Medicine, Mobile, AL 36688, USA
    J Mol Cell Cardiol 43:262-71. 2007
    ..We propose that the key protective event in IPC occurs when PKC increases the heart's sensitivity to adenosine so that endogenous adenosine can activate A(2b)-dependent signaling...
  46. ncbi Effect of inhaled roflumilast on the prevention and resolution of allergen-induced late phase airflow obstruction in Brown Norway rats
    Richard W Chapman
    Schering Plough Research Institute, Pulmonary and Peripheral Neurobiology M S 1700, 2015 Galloping Hill Road, Kenilworth, NJ 07033, United States
    Eur J Pharmacol 571:215-21. 2007
    ..These results support the development of inhaled PDE4 inhibitors for the treatment of asthma and COPD, particularly for the improvement of lung function...
  47. ncbi Effectiveness of two oral pastes for the treatment of recurrent aphthous stomatitis
    M Rodriguez
    Facultad de Odontologia, Universidad Nacional de Colombia, Bogota, Colombia
    Oral Dis 13:490-4. 2007
    ..To compare the effectiveness of two topical medications to reduce the pain and size of recurrent minor aphthous ulcers...
  48. ncbi Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis
    Robert Hermann
    Exploratory Medicine, ALTANA Pharma AG, Konstanz, Germany
    Clin Pharmacokinet 46:403-16. 2007
    ..Roflumilast is being developed for the treatment of inflammatory airway diseases such as chronic obstructive pulmonary disease and asthma...
  49. ncbi Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast
    Nassr Nassr
    Department of Exploratory Medicine, ALTANA Pharma AG, Byk-Gulden-Str. 2, 78467 Konstanz, Germany
    J Clin Pharmacol 47:660-6. 2007
  50. ncbi Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors
    Tobias Eckle
    Department of Anesthesiology and Intensive Care Medicine, Tubingen University Hospital, Hoppe Seyler Str 3, D 72076 Tubingen, Germany
    Circulation 115:1581-90. 2007
    ..Once generated, adenosine can activate cell-surface adenosine receptors (A1 AR, A2A AR, A2B AR, A3 AR). In the present study, we define the contribution of adenosine to cardioprotection by ischemic preconditioning...
  51. ncbi Anxiolytic-like activity of SB-205384 in the elevated plus-maze test in mice
    Jose Francisco Navarro
    Facultad de Psicologia, Universidad de Malaga, Spain
    Psicothema 18:100-4. 2006
    ..These findings indicate that SB-205384 exhibits an anxiolytic-like profile in the elevated plus-maze test, suggesting that GABA-A receptors which contain the alpha3 subunit might be involved in regulation of anxiety...
  52. ncbi Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide
    G Lahu
    Nycomed GmbH formerly ALTANA Pharma AG, Konstanz, Germany
    Int J Clin Pharmacol Ther 47:236-45. 2009
    ..Both roflumilast and roflumilast N-oxide have similar intrinsic PDE4 inhibitory activity; the total PDE4 inhibition (tPDE4i) in humans is likely due to the combined effect of roflumilast and roflumilast N-oxide...
  53. ncbi Metal-free catalysts for the hydrolysis of RNA derived from guanidines, 2-aminopyridines, and 2-aminobenzimidazoles
    Ute Scheffer
    Institute for Organic Chemistry and Chemical Biology, Goethe-University Frankfurt, Marie-Curie-Str. 11, 60439 Frankfurt am Main, Germany
    J Am Chem Soc 127:2211-7. 2005
    ..Conjugates of 10b with antisense oligonucleotides or RNA binding peptides, therefore, will be promising candidates as site specific artificial ribonucleases...
  54. ncbi Treatment strategies for recurrent oral aphthous ulcers
    R W Barrons
    Clinical Pharmacy, Xavier University of Louisiana, 1 Drexel Street, New Orleans, LA 70125 1098, USA
    Am J Health Syst Pharm 58:41-50; quiz 51-3. 2001
    ..Thalidomide is effective but, because of its toxicity and cost, should be used only as an alternative to oral corticosteroids. RAU can be effectively managed with a variety of topical and systemic medications...
  55. ncbi In vivo evidence that 5-HT2C receptor antagonist but not agonist modulates cocaine-induced dopamine outflow in the rat nucleus accumbens and striatum
    Sylvia Navailles
    UMR CNRS, , Bordeaux Cedex, France
    Neuropsychopharmacology 29:319-26. 2004
    ..Furthermore, they show that 5-HT(2C) agonists, at variance with 5-HT(2C) antagonists, exert a preferential control on the impulse-stimulated release of DA...
  56. ncbi Inhibition of inflammation and remodeling by roflumilast and dexamethasone in murine chronic asthma
    Rakesh K Kumar
    Department of Pathology, University of New South Wales, Sydney, Australia
    J Pharmacol Exp Ther 307:349-55. 2003
    ..Roflumilast did not diminish accumulation of transforming growth factor-beta1, suggesting that it might affect remodeling by mechanisms distinct from glucocorticoids...
  57. ncbi The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro
    N A Jones
    Sackler Institute of Pulmonary Pharmacology, 5th Floor Hodgkin Building, Guy's Campus, St Thomas' School of Biomedical Sciences, King's College, London SE1 1UL, UK
    Pulm Pharmacol Ther 18:93-101. 2005
    ..These data provide further evidence that selective PDE4 isoenzyme inhibitors can inhibit neutrophil degranulation, effects not shared by PDE3 inhibitors or theophylline...
  58. ncbi Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family
    T Shishibori
    Department of Chemistry, Kagawa Medical University, 1750 1, Miki cho, Kita gun, 761 0793 Kagawa, Japan
    Biochem J 338:583-9. 1999
    ..On the basis of these findings, we speculate that the three anti-allergic drugs might inhibit degranulation by binding with S100A12 and S100A13...
  59. ncbi In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor
    D S Bundschuh
    Department of Pharmacology, Byk Gulden, P O Box 10 03 10, 78403 Konstanz, Germany
    J Pharmacol Exp Ther 297:280-90. 2001
    ..These results, coupled with the in vitro effects of roflumilast on inflammatory cells, suggest that roflumilast represents a potential new drug for the treatment of asthma and chronic obstructive pulmonary disease...
  60. ncbi Phosphodiesterase 4 inhibitors for the treatment of COPD
    Graham Sturton
    Bayer plc, Pharma Research, Stoke Court, Stoke Poges, Slough SL2 4LY, Berkshire, UK
    Chest 121:192S-196S. 2002
    ..The initial clinical data on the most advanced compound, cilomilast, were indeed encouraging. However, full knowledge of the therapeutic value of this novel compound class awaits the outcome of longer term clinical trials...
  61. ncbi 2-aminopyridines as highly selective inducible nitric oxide synthase inhibitors. Differential binding modes dependent on nitrogen substitution
    Stephen Connolly
    Medicinal Chemistry, Discovery Bioscience, Molecular Biology and Physical and Metabolic Sciences Departments, AstraZeneca R and D Charnwood, Bakewell Road, Loughborough, Leics LE11 5RH, U K
    J Med Chem 47:3320-3. 2004
    ..Evidently, a flipping of the pyridine ring between these new inhibitors allows the piperidine to interact with different residues and confer excellent selectivity...
  62. ncbi The 5-HT(4) agonists cisapride, mosapride, and CJ-033466, a Novel potent compound, exhibit different human ether-a-go-go-related gene (hERG)-blocking activities
    Tetsuo Toga
    Nagoya Laboratories, Pfizer Global Research and Development, Pfizer Japan Inc, Taketoyo, Aichi, Japan
    J Pharmacol Sci 105:207-10. 2007
    ..Therefore, CJ-033466 has the potential to be a drug with higher therapeutic efficacy and less cardiac risk than both cisapride and mosapride...
  63. ncbi A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats
    David H Overstreet
    Department of Psychiatry, Bowles Center for Alcohol Studies, University of North Carolina School of Medicine, CB 7178, Chapel Hill, NC 27599 7178, USA
    Psychopharmacology (Berl) 167:344-52. 2003
    ..The deficits in social interaction behavior following withdrawal from continuous ethanol exposure can be reduced following acute treatments with 5-HT(2C) antagonists or 5-HT(1A) agonists...
  64. ncbi 5-HT(2C) receptor activation is a common mechanism on proerectile effects of apomorphine, oxytocin and melanotan-II in rats
    Yasuharu Kimura
    Pharmacology Research Labs, Drug Discovery Research, Astellas Pharma Inc, Tsukuba shi, Ibaraki, Japan
    Eur J Pharmacol 589:157-62. 2008
    ....
  65. ncbi Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors
    A A Harrison
    Department of Neuropharmacology, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037, USA
    J Pharmacol Exp Ther 297:316-25. 2001
    ..In conclusion, the present data support the hypothesis that serotonin exerts an inhibitory influence on reward processes...
  66. ncbi Influence of the 5-HT(2C) receptor antagonist SB242,084 on behaviour produced by the 5-HT(2) agonist Ro60-0175 and the indirect 5-HT agonist dexfenfluramine
    G A Higgins
    PRBN-B, F. Hoffmann-La Roche Ltd, CH-4070, Basel, Switzerland
    Br J Pharmacol 133:459-66. 2001
    ..An attenuation of the hyperlocomotor response was also observed following MDL100,907. These findings suggest that 5-HT(2C) receptor activation can inhibit the expression of behaviours mediated through other 5-HT receptor subtypes...
  67. ncbi A reporter gene assay for screening of PDE4 subtype selective inhibitors
    Roop Singh Bora
    Department of Biotechnology, Ranbaxy Research Laboratories, Plot No 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon, Haryana 122001, India
    Biochem Biophys Res Commun 356:153-8. 2007
    ..This methods provide a novel, simple and sensitive assay for high throughput screening of PDE4 subtype selective inhibitors for treatment of asthma and COPD...
  68. ncbi Activation of 5-HT(2C) receptors reduces the locomotor and rewarding effects of nicotine
    A J Grottick
    PRBN-B, F. Hoffmann-La Roche Ltd, Basel, Switzerland
    Psychopharmacology (Berl) 157:292-8. 2001
    ..CONCLUSIONS: The present data support an involvement for the 5-HT(2C) receptor in mediating mesolimbic DA functioning as assessed by changes in behaviours indicative of nicotine reward...
  69. ncbi Activation of the serotonergic 5-HT1A receptor in the paraventricular nucleus of the hypothalamus inhibits water intake and increases urinary excretion in water-deprived rats
    Patrícia de Souza Villa
    Department of Physiology, São Paulo State University at Araraquara, UNESP, Brazil
    Regul Pept 150:14-20. 2008
    ..We suggest that antidipsogenic and diuretic responses seem to be mediated via 5-HT(1A) receptors of the lateral-medial posterior magnocellular region of the PVN in water-deprived rats...
  70. ncbi Serotonin 1A receptor agonists reverse respiratory abnormalities in spinal cord-injured rats
    Yang Dong Teng
    Department of Pharmacology, Georgetown University Medical Center, Washington, DC 20057, USA
    J Neurosci 23:4182-9. 2003
    ..p.; n = 3) given 20 min before 8-OH-DPAT, prevented 8-OH-DPAT from restoring respiration to normal. Our results demonstrate that drugs that stimulate 5-HT1A receptors counteract respiratory abnormalities in conscious rats after SCI...
  71. ncbi m-CPP-induced self-grooming is mediated by 5-HT2C receptors
    Marton Graf
    Laboratory of Neurochemistry and Experimental Medicine, National Institute of Psychiatry and Neurology, Huvosvolgyi ut 116, Budapest H-1021, Hungary
    Behav Brain Res 142:175-9. 2003
    ..Our studies provide evidence that direct activation of 5-HT(2C) receptors mediate m-CPP-induced self-grooming and the depletion of brain 5-HT sensitizes these receptors...
  72. ncbi 5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation
    Elizabeth A Hackler
    Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    J Pharmacol Exp Ther 320:1023-9. 2007
    ..In conclusion, the brain activation signals produced by anxiogenic doses of both m-CPP and FG-7142 are mediated at least partially by the 5-HT(2C) receptor, indicating that this receptor is a key component in anxiogenic neural circuitry...
  73. ncbi L-454,560, a potent and selective PDE4 inhibitor with in vivo efficacy in animal models of asthma and cognition
    Z Huang
    Department of Biochemistry and Molecular Biology, Merck Frosst Centre for Therapeutic Research, Kirkland, Quebec, Canada
    Biochem Pharmacol 73:1971-81. 2007
    ..Therefore, L-454,560 is a novel PDE4 inhibitor with an overall in vivo efficacy profile at least comparable to roflumilast and clearly superior to cilomilast...
  74. ncbi Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol- l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine(2C) receptor agonist
    K J Damjanoska
    Department of Pharmacology and Experimental Therapeutics, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA
    J Pharmacol Exp Ther 304:1209-16. 2003
    ..The data suggest that Ro 60-0175 increases hormone secretion by mechanisms independent of the activation of 5-HT(2C) and/or 5-HT(2A) receptors and suggest that Ro 60-0175 is not a highly selective 5-HT(2C) receptor agonist...
  75. ncbi Discriminative stimulus properties of 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane [(+/-)DOI] in C57BL/6J mice
    Randy L Smith
    Department of Psychiatry, Vanderbilt University School of Medicine, Nashville, TN 37232, USA
    Psychopharmacology (Berl) 166:61-8. 2003
    ....
  76. ncbi Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization
    William J Thomsen
    Arena Pharmaceuticals, Inc, 6166 Nancy Ridge Dr, San Diego, CA 92121, USA
    J Pharmacol Exp Ther 325:577-87. 2008
    ..Upon discontinuation, body weight returned to control levels. These data demonstrate lorcaserin to be a potent, selective, and efficacious agonist of the 5-HT(2C) receptor, with potential for the treatment of obesity...
  77. ncbi PDE4 inhibitor, roflumilast protects cardiomyocytes against NO-induced apoptosis via activation of PKA and Epac dual pathways
    Hyun Jeong Kwak
    Division of Cardiovascular Diseases, Department of Biomedical Sciences, National Institutes of Health, 194 Tongillo, Eunpyung Gu, Seoul 122 701, Republic of Korea
    Cell Signal 20:803-14. 2008
    ..Our study suggests a possibility of PDE4 inhibitor roflumilast as a potential therapeutic agent against myocardial ischemia/reperfusion (I/R) injury...
  78. ncbi Ejaculatory response induced by a 5-HT2 receptor agonist m-CPP in rats: differential roles of 5-HT2 receptor subtypes
    Akihiko Yonezawa
    Department of Physiology and Anatomy, Tohoku Pharmaceutical University, 4 4 1 Komatsushima, Aoba ku, Sendai 981 8558, Japan
    Pharmacol Biochem Behav 88:367-73. 2008
    ..0 mg/kg) of m-CPP. Furthermore, the results of the present study also indicate that the corset test employed in this study may be useful for detecting the proejaculatory effect of the compounds...
  79. ncbi Inhibition of phosphodiesterase type 4 decreases stress-induced defecation in rats and mice
    Frank C Barone
    Discovery Research, High Throughput Biology, GlaxoSmithKline, King of Prussia, PA 19406, USA
    Pharmacology 81:11-7. 2008
    ..In this study, the effects of PDE4 inhibition were assessed in a model of stress-induced defecation previously demonstrated to be due to increased colonic transit/evacuation...
  80. ncbi Comparison of the potency of MDL 100,907 and SB 242084 in blocking the serotonin (5-HT)(2) receptor agonist-induced increases in rat serum corticosterone concentrations: evidence for 5-HT(2A) receptor mediation of the HPA axis
    Susan K Hemrick-Luecke
    Neuroscience Research Division, Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Drop Code 0510, Indianapolis, IN 46285, USA
    Neuropharmacology 42:162-9. 2002
    ..Our findings implicate 5-HT(2A) receptors rather than 5-HT(2C) receptors in mediating increases in rat serum corticosterone produced by direct-acting 5-HT(2) receptor agonists in vivo...
  81. ncbi Characterization of 4-(2-hydroxyphenyl)-1-[2'-[N-(2''-pyridinyl)-p-fluorobenzamido]ethyl]piperazine (p-DMPPF) as a new potent 5-HT1A antagonist
    C Defraiteur
    Cyclotron Research Center, Liege University, Liege, Belgium
    Br J Pharmacol 152:952-8. 2007
    ....
  82. ncbi Rikkunshito, an herbal medicine, suppresses cisplatin-induced anorexia in rats via 5-HT2 receptor antagonism
    Hiroshi Takeda
    Department of Gastroenterology and Hematology, Hokkaido University Graduate School of Medicine, Kita ku, Sapporo, Japan
    Gastroenterology 134:2004-13. 2008
    ..Rikkunshito, a kampo preparation, is known to alleviate such adverse reactions. In this study, we attempted to clarify the mechanism...
  83. ncbi m-Chlorophenylpiperazine excites non-dopaminergic neurons in the rat substantia nigra and ventral tegmental area by activating serotonin-2C receptors
    G Di Giovanni
    Istituto di Ricerche Farmacologiche Mario Negri, Consorzio Mario Negri Sud, 66030 Santa Maria Imbaro (Chieti, Italy
    Neuroscience 103:111-6. 2001
    ..It is concluded that stimulation of serotonin-2C receptors by m-chlorophenylpiperazine activates non-dopaminergic (presumably GABA-containing) neurons in the substantia nigra pars reticulata and ventral tegmental area...
  84. ncbi Lack of DNA binding in the rat nasal mucosa and other tissues of the nasal toxicants roflumilast, a phosphodiesterase 4 inhibitor, and a metabolite, 4-amino-3,5-dichloropyridine, in contrast to the nasal carcinogen 2,6-dimethylaniline
    Alan M Jeffrey
    New York Medical College, Department of Pathology, Valhalla, NY 10595, USA
    Drug Chem Toxicol 25:93-107. 2002
    ..In the absence of a pattern of compound-related spots, we conclude that RF does not form DNA adducts having the potential to initiate neoplasia in these three tissues...
  85. ncbi Serotonin 2C receptor agonists and the behavioural satiety sequence in mice
    Katherine N Hewitt
    Laboratory of Experimental Psychology, University of Sussex, Falmer, Brighton, Sussex BN1 9QG, UK
    Pharmacol Biochem Behav 71:691-700. 2002
    ..These data suggest that Ro 60-0175- and mCPP-induced hypophagia in mice are mediated via activation of 5-HT(2C) receptors and that stimulation of 5-HT(1B) receptors plays only a minor role in mCPP-induced hypophagia...
  86. ncbi Dissociation of systemic and hippocampal modulation of rat locomotor activity by 5-HT(2C) receptors
    H Takahashi
    Department of Physiology, School of Medicine, Hamamatsu University, 3600 Handa-cho, Hamamatsu-shi, Shizuoka-ken 431-3192, Japan
    Neurosci Res 40:97-103. 2001
    ..The present study demonstrates that the 5-HT(2C) receptors in the hippocampus act to increase rat locomotor activity...
  87. ncbi Effects of the serotonin 5-HT2A and 5-HT2C receptor ligands on the discriminative stimulus effects of nicotine in rats
    Magdalena Zaniewska
    Laboratory of Drug Addiction Pharmacology, Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 31 343 Krakow, 12 Smetna, Poland
    Eur J Pharmacol 571:156-65. 2007
    ....
  88. ncbi Stimulation of 5-hydroxytryptamine (5-HT(2C) ) receptors in the ventrotegmental area inhibits stress-induced but not basal dopamine release in the rat prefrontal cortex
    Laura Pozzi
    Mario Negri Institute of Pharmacological Research, Via Eritrea 62, 20157 Milan, Italy
    J Neurochem 82:93-100. 2002
    ....
  89. ncbi 5-HT2C receptor mediation of unconditioned escape behaviour in the unstable elevated exposed plus maze
    Nicholas Jones
    Department of Psychology, University College London, Gower Street, London WC1E 6BT, UK
    Psychopharmacology (Berl) 164:214-20. 2002
    ..This study aimed to examine the involvement of the 5-HT2C receptor in the unconditioned fear responses observed in the UEEPM (after an acute dose of mCPP) by pre-treatment with the selective 5-HT2C receptor antagonist SB-242084...
  90. ncbi LABORAS: Initial pharmacological validation of a system allowing continuous monitoring of laboratory rodent behaviour
    Leann P Quinn
    Neurology and GI CEDD, GlaxoSmithKline Pharmaceuticals, New Frontiers Science Park, Third Avenue, Harlow, Essex CM19 5AW, UK
    J Neurosci Methods 130:83-92. 2003
    ....
  91. ncbi Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3,5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations
    Regina Draheim
    Department of Pharmacology, elbion AG, Radebeul, Germany
    J Pharmacol Exp Ther 308:555-63. 2004
    ..The reduced activity in human blood may be related to high plasma protein binding. Currently, phase II clinical studies are under way to evaluate the therapeutic potential of AWD 12-281 in asthma, COPD, and allergic rhinitis...
  92. ncbi Roflumilast, a phosphodiesterase 4 inhibitor, reduces airway hyperresponsiveness after allergen challenge
    C Louw
    Internal Medicine, Lung and Allergy Unit, University of Stellenbosch, School of Medicine, Cape Town, South Africa
    Respiration 74:411-7. 2007
    ..Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, is currently in clinical development for the treatment of asthma...
  93. ncbi Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade
    Agnès L Auclair
    Division of Neurobiology 2, Centre de Recherche Pierre Fabre, Castres, France
    Neuropsychopharmacology 31:1900-9. 2006
    ....
  94. ncbi [Phosphosdiesterase 4 inhibitors in the treatment of pulmonary diseases]
    Xiao-dong Xia
    Zhonghua Jie He He Hu Xi Za Zhi 27:57-9. 2004
  95. ncbi Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma
    J Bousquet
    , Montpellier, France
    Allergy 61:72-8. 2006
    ..CONCLUSIONS: Once daily, oral roflumilast 500 microg was comparable with inhaled twice-daily BDP (400 microg/day) in improving pulmonary function and asthma symptoms, and reducing rescue medication use in patients with asthma...
  96. ncbi Role of 5-HT receptor antagonists in mediating intracavernous pressure response induced by fluvoxamine in conscious rats
    Naoki Aizawa
    Department of Urology, Shinshu University School of Medicine, Matsumoto, Japan
    J Sex Med 4:1108-16. 2007
    ..It has been reported that selective serotonin reuptake inhibitor (SSRI) may cause sexual dysfunction...
  97. ncbi ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens
    Zhu Li
    Psychiatry Department, Psychopharmacology Division, Vanderbilt University School of Medicine, Suite 306, 1601 23rd Ave S, Nashville, TN 37212, USA
    Psychopharmacology (Berl) 183:144-53. 2005
    ..However, pretreatment with the 5-HT(2A/2C) receptor antagonist SR46349-B with haloperidol increased both mPFC and NAC DA release, suggesting that both 5-HT(2A) and 5-HT(2C) properties may be important for atypical APD effects...
  98. ncbi Clozapine and haloperidol differentially alter the constitutive activity of central serotonin2C receptors in vivo
    Sylvia Navailles
    , Bordeaux Cedex, France
    Biol Psychiatry 59:568-75. 2006
    ..3 and 1 mg/kg). CONCLUSIONS: These results show that clozapine and haloperidol differentially alter the constitutive activity of 5-HT2C receptors and suggest that clozapine behaves as a 5-HT2C inverse agonist in vivo...
  99. ncbi WAY 405, a new silent 5-HT (1A) receptor antagonist with low affinity for vascular alpha (1)-adrenoceptors
    R Villalobos-Molina
    , ,
    Auton Autacoid Pharmacol 25:185-9. 2005
    ..4 The results show that in the control of blood pressure the new compound, WAY 405, behaves as a silent 5-HT(1A) receptor antagonist in the anaesthetized rat, also having low affinity for vascular alpha(1)-adrenoceptors...
  100. ncbi Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens
    Philippe De Deurwaerdère
    Unité Mixte de Recherche Centre National de la Recherche Scientifique 5541 Université Victor Segalen Bordeaux 2, Boîte Postale 31, 33076 Bordeaux Cedex, France
    J Neurosci 24:3235-41. 2004
    ....
  101. ncbi Despite similar anxiolytic potential, the 5-hydroxytryptamine 2C receptor antagonist SB-242084 [6-chloro-5-methyl-1-[2-(2-methylpyrid-3-yloxy)-pyrid-5-yl carbamoyl] indoline] and chlordiazepoxide produced differential effects on electroencephalogram power
    Sandor Kantor
    Laboratory of Neurochemistry and Experimental Medicine, National Institute of Psychiatry and Neurology, Budapest, Hungary
    J Pharmacol Exp Ther 315:921-30. 2005
    ..In contrast, acute CDP administration, based on spectral analysis of the EEG, produced a more superficial sleep along with a decreased activity...

Research Grants103 found, 100 shown here

  1. STRUCTURE-FUNCTION IN LOW-RESISTANCE JUNCTIONS
    Camillo Peracchia; Fiscal Year: 1993
    ..by testing their potential interaction with amphiphilic connexin domains and the effects of xanthines and aminopyridines. The nature of extracellular connexin-connexin interactions will be studied by expressing connexins ..
  2. METVAN: A Novel Anticancer Agent
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The knowledge gained from these studies described under Specific Aims 1-2 is expected to facilitate the design of innovative treatment regimens employing METVAN for metastatic breast cancer and brain tumor patients. ..
  3. FLP-102: Rationally Engineered Antiviral Protein
    OSMOND D CRUZ; Fiscal Year: 2003
    ..The preclinical data on FLP-102 will be essential to further explore the utility of this novel recombinant PAP mutant for Phase II. ..
  4. Stampidine: A Novel Broad-Spectrum Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
    ..Specific Aims 1 and 2 may provide the foundation for the clinical development of STAMP in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
  5. Phase II SBIR: WHI-07: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2005
    ....
  6. Transmitter Repletion: Key to Phrenic-Diaphragm Function
    Erik van Lunteren; Fiscal Year: 2005
    ..These studies may lead to novel therapeutic approaches to respiratory muscle impairment and resulting hypercapnic respiratory failure for conditions which produce neuromuscular junction dysfunction. ..
  7. NOVEL CONTRACEPTIVES WITH ANTI-HIV ACTIVITY
    OSMOND D CRUZ; Fiscal Year: 2001
    ..The preclinical data on in vivo efficacies of WHI-05 and WHI-07 will be essential to further explore the utility of these novel drugs for clinical studies in human patients. ..
  8. PHI 346: A Novel Dual-Function Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
    ..Following successful completion of the Phase I in vivo efficacy studies, gel formulation of PHI-346 will be further explored as a vaginal dual-function microbicide in Phase II. ..
  9. PHI-443: Novel Non-Spermicidal Anti-HIV Microbicide
    OSMOND D CRUZ; Fiscal Year: 2003
    ..Specific Aims 1 and 2 may provide the foundation for the clinical development of PHI-443 in Phase II studies as a safe, effective broad-spectrum anti-HIV microbicide without conception-inhibiting functions. ..
  10. Vanadocenes as a New Class of Spermicidal Drugs
    OSMOND D CRUZ; Fiscal Year: 2007
    ....
  11. Viral-induced Adaptation of Neutrophil Response in ARDS
    JERRY NICK; Fiscal Year: 2007
    ..End of Abstract) ..
  12. Effects of Chronic THC in Adolescence
    Peter J Winsauer; Fiscal Year: 2010
    ..Together, data from these experiments will demonstrate how drug abuse and hormonal status during adolescence may permanently alter brain function and the liability of subsequent abuse of A9-THC. ..
  13. Neural Mechanism of Drug-Seeking Behavior
    Janet L Neisewander; Fiscal Year: 2010
    ..Understanding these circuits will likely have important implications for developing treatments for cocaine dependence. ..
  14. A Thermo Electron LTQ Mass Spectrometer
    Joseph Zaia; Fiscal Year: 2006
    ..The costs of instrument operation, supplies, and service contract will be shared by the users, as stated in their support letters. The salary for the instrument operator will be provided by the Dean of BU School of Medicine. ..
  15. Drugs as conditioned reinforcers and/or enhancers of social reward in adolescents
    Janet Neisewander; Fiscal Year: 2007
    ..The findings could potentially initiate a line of investigation on neural mechanisms involved in these interactions, which may in turn provide insight for understanding and treating drug abuse and dependence. ..
  16. Molecular Epidemiology, Virulence, and Genomic Characterization of Ureaplasmas
    Ken Waites; Fiscal Year: 2007
    ....
  17. CHEMICAL/BEHAVIORAL STUDIES ON HALLUCINOGENIC AGENTS
    RICHARD GLENNON; Fiscal Year: 2007
    ..This will eventually lead to a better understanding of abuse prevention and treatment modalities. ..
  18. CB1 Modulation of Opioid Peptides and Ethanol Intake
    Loren Parsons; Fiscal Year: 2007
    ..abstract_text> ..
  19. 5-HTIB RECEPTORS AND MECHANISMS OF ETHANOL REINFORCEMENT
    Loren Parsons; Fiscal Year: 2005
    ..abstract_text> ..
  20. CHEMICAL/BEHAVIORAL STUDIES ON HALLUCINOGENIC AGENTS
    RICHARD GLENNON; Fiscal Year: 1993
    ..New agents are proposed for synthesis that will aid in solving these problems...
  21. Limbic-cortical involvement in drug seeking
    Janet Neisewander; Fiscal Year: 2006
    ..The findings may be useful for developing behavioral and pharmacological treatments for cocaine dependence. ..
  22. BEHAVIORAL & PHARMACOLOGICAL ANALYSIS OF DRUGS OF ABUSE
    JERROLD WINTER; Fiscal Year: 1991
    ..A long-term objective of the proposed research is to achieve an understanding of these complex behavioral effects in biochemical terms and thus to facilitate rational clinical intervention...
  23. Neural Mechanism of Drug-Seeking Behavior
    Janet L Neisewander; Fiscal Year: 2010
    ..Understanding these circuits will likely have important implications for developing treatments for cocaine dependence. ..
  24. AMBIENT PARTICULATE MATTERS POISON CARDIAC ION CHANNELS
    Desuo Wang; Fiscal Year: 2005
    ....
  25. NEURAL MECHANISMS OF DRUG SEEKING BEHAVIOR
    Janet Neisewander; Fiscal Year: 2000
    ..If confirmed, the findings would suggest a new pharmacologic treatment strategy for cocaine dependence. ..
  26. CNS VIRAL INJURY AND VULNERABILITY TO OPIATE DRUG ABUSE
    Marylou Solbrig; Fiscal Year: 2002
    ..At the conclusion of the grant period, the requisite skills in behavioral pharmacology, neuropharmacology and molecular biology for continued work in the study and treatment of drug addiction will have been acquired by the candidate. ..
  27. EFFECTS OF DIOXINS (TCDD) ON CARDIAC ION CHANNELS
    Desuo Wang; Fiscal Year: 2003
    ....
  28. BEHAVIORAL AND PHARMACOLOGIC ANALYSIS OF DRUG OF ABUSE
    JERROLD WINTER; Fiscal Year: 2000
    ....
  29. Viral neuropathology neuropeptides and epilepsy
    Marylou Solbrig; Fiscal Year: 2005
    ....
  30. NEURAL MECHANISMS OF DRUG SEEKING BEHAVIOR
    Janet Neisewander; Fiscal Year: 2005
    ..These experiments will help to elucidate 5-HT mechanisms involved in incentive motivation for cocaine and will likely have important implications for developing treatments for cocaine dependence. ..
  31. INFLAMMATION & CORTICOSTEROID RESPONSES IN SEVERE ASTHMA
    KIAN CHUNG; Fiscal Year: 2005
    ..The molecular mechanisms underlying loss of CR will be examined. These studies should lead to more effective therapies for chronic severe asthma. ..
  32. BEHAVIORAL & PHARMACOLOGICAL ANALYSIS OF DRUGS OF ABUSE
    JERROLD WINTER; Fiscal Year: 2005
    ..abstract_text> ..
  33. Glycosaminoglycan-Protein Binding
    Joseph Zaia; Fiscal Year: 2006
    ..abstract_text> ..